Non-Invasive Prenatal Testing (NIPT)

Non-Invasive Prenatal Testing (NIPT)

Global Non-Invasive Prenatal Testing (NIPT) Market to Reach US$9.2 Billion by 2030

The global market for Non-Invasive Prenatal Testing (NIPT) estimated at US$4.5 Billion in the year 2023, is expected to reach US$9.2 Billion by 2030, growing at a CAGR of 10.7% over the analysis period 2023-2030. NIPT Consumables & Reagents, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$5.5 Billion by the end of the analysis period. Growth in the NIPT Instruments segment is estimated at 14.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 13.7% CAGR

The Non-Invasive Prenatal Testing (NIPT) market in the U.S. is estimated at US$1.2 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 13.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.0% CAGR.

Global Non-Invasive Prenatal Testing (NIPT) Market - Key Trends and Drivers Summarized

Why Is Non-Invasive Prenatal Testing (NIPT) Gaining Ground in Prenatal Care?

Non-Invasive Prenatal Testing (NIPT) is rapidly transforming prenatal care by offering expectant parents a safer and more accurate method for detecting chromosomal abnormalities in the fetus. NIPT analyzes cell-free fetal DNA present in the mother’s blood to identify genetic conditions like Down syndrome, Edwards syndrome, and Patau syndrome. Unlike traditional invasive procedures like amniocentesis or chorionic villus sampling, which carry risks of miscarriage, NIPT provides reliable results with minimal risk. The test is typically performed during the first trimester and is suitable for high-risk pregnancies, enabling early decision-making and better management of prenatal care. As awareness of genetic screening increases, NIPT is becoming an integral part of routine prenatal screening.

What Are the Key Segments in the NIPT Market?

Key technologies include next-generation sequencing (NGS), microarray, and polymerase chain reaction (PCR), with NGS being the most widely used due to its high accuracy and ability to detect multiple genetic markers simultaneously. In terms of application, NIPT is primarily used for detecting trisomies, including Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13). Other applications include detecting sex chromosome abnormalities and microdeletions. The major end-users of NIPT include hospitals, diagnostic laboratories, and maternity clinics, where genetic testing is becoming a standard component of prenatal care, particularly for women over 35 or those with a history of genetic disorders.

How Is NIPT Integrated Across Prenatal Care and Diagnostics?

Hospitals and maternity clinics are incorporating NIPT as part of routine prenatal screening for high-risk pregnancies, where early detection of chromosomal abnormalities is crucial for medical decision-making. Diagnostic laboratories use NIPT to offer comprehensive genetic screening services, often in collaboration with healthcare providers to ensure timely results and follow-up care. Research institutions are exploring the potential of NIPT beyond chromosomal abnormalities, including screening for single-gene disorders and broader genetic insights. Additionally, telehealth services are facilitating remote consultations and access to NIPT, making it more accessible to pregnant women in underserved regions. The growing awareness and acceptance of NIPT among healthcare providers and expectant parents underscore its role in modern prenatal care.

What Factors Are Driving the Growth in the Non-Invasive Prenatal Testing (NIPT) Market?

The growth in the Non-Invasive Prenatal Testing (NIPT) market is driven by several factors, including the increasing demand for early and accurate prenatal screening, particularly in high-risk pregnancies. Advances in next-generation sequencing and other genetic analysis technologies have improved the accuracy, efficiency, and affordability of NIPT, making it more accessible. The rising awareness of genetic disorders and the benefits of early detection have also contributed to the broader adoption of NIPT. Regulatory approvals for NIPT in several countries, combined with government support for maternal healthcare, have further fueled market growth. Additionally, the expansion of telehealth services and direct-to-consumer testing models has made NIPT more accessible, increasing its adoption among expectant mothers worldwide.

Select Competitors (Total 33 Featured) -

• Agilent Technologies, Inc.
• Berry Genetics Inc.
• BGI Genomics Co. Ltd.
• Eurofins LifeCodexx GmbH
• F. Hoffmann-La Roche Ltd.
• GE Healthcare
• Igenomix
• Illumina, Inc.
• Laboratory Corporation of America Holdings
• Natera, Inc.
• PerkinElmer Inc.
• Thermo Fisher Scientific Inc.
• Yourgene Health

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.